Over 100,000 people suffer from multiple sclerosis in Germany alone. Despite intensive research, the factors that trigger the disease and influence its progress remain unclear. Scientists from the Max Planck Institute of Neurobiology in Martinsried and an international research team have succeeded in attaining three important new insights into the...
Latest News
BOSTON — Tract Bio, a biotechnology company discovering and developing novel therapies for cancer and inflammatory disease, today announced the publication of a research article in the American Journal of Respiratory and Critical Care Medicine (AJRCCM) highlighting the stem cell variants driving chronic lung inflammation in modulator-treated cystic fibrosis patients...
COLUMBIA, Missouri – As one of the most insidious diseases in the world, cancer has few treatments that work to eradicate it completely. Now, a new ground-breaking approach pioneered by two researchers working at the University of Missouri’s Roy Blunt NextGen Precision Health building shows promising results in preventing lung...
SAN DIEGO, CA — Travere Therapeutics Inc. (Nasdaq: TVTX) today announced the completion of a successful pre-NDA meeting with the U.S. Food and Drug Administration (FDA) for FILSPARI® (sparsentan) in IgA nephropathy (IgAN). The Company will submit a supplemental New Drug Application (sNDA) in the first quarter of 2024 for...
SAN DIEGO — Travere Therapeutics, Inc. (NASDAQ: TVTX) announced that the interim analysis of efficacy and safety data from the ongoing Phase 3 PROTECT Study evaluating FILSPARI™ (sparsentan) in IgA nephropathy (IgAN) will be presented in late-breaking trial sessions at both the ISN World Congress of Nephrology in Bangkok, Thailand,...
Treatment with highest dose pegtibatinase led to a clinically meaningful 55% mean reduction in total homocysteine from baseline and was generally well-tolerated after 12 weeks of treatment Results provide clinical proof of concept for first potential therapy targeting the underlying enzyme deficiency in classical homocystinuria SAN DIEGO – Travere Therapeutics,...
SAN DIEGO – Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced completion of patient enrollment in the Phase 3 PROTECT Study. The pivotal PROTECT Study is evaluating the safety and efficacy of sparsentan for the treatment of IgA nephropathy (IgAN), a rare kidney disorder that often progresses to end-stage kidney disease...
SAN DIEGO, Calif. — Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for conversion of the existing U.S. accelerated approval of FILSPARI® (sparsentan) in IgA nephropathy (IgAN) to full approval. In February 2023, the...
San Diego, Calif. – Travere Therapeutics on Friday released more data from the Phase III PROTECT and DUPLEX studies—in IgA nephropathy and focal segmental glomerulosclerosis, respectively—showing that treatment with Filspari (sparsentan) can preserve kidney function in these diseases. The results were presented at the American Society of Nephrology’s Kidney Week...
A pilot study by a team of multiple sclerosis (MS) researchers showed that treadmill walking exercise training may be an effective approach to managing the debilitating cognitive effects of the disease. Their article, titled, “Effects of walking exercise training on learning and memory and hippocampal neuroimaging outcomes in MS: A...